Matthew Grunwald, MD
Gastroenterology · Portland, MENPI 1689061954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Fujifilm Healthcare Americas Corporation at 27.5% of the total. 2025 is the largest year on record at $421, more than ten times the $35 reported in 2021.
Across 26 payments — averaging $30.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fujifilm Healthcare Americas Corporation$221
- Sanofi$162
- Gilead$87
- Ipsen Biopharmaceuticals, Inc$69
- Johnson & Johnson$54
- Boston Scientific$35
- plus $176 from 7 others
What the payments were for
- Food & beverage$805100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fujifilm Healthcare Americas Corporation | 4 | $221 |
| Sanofi | 5 | $162 |
| Gilead | 3 | $87 |
| Ipsen Biopharmaceuticals, Inc | 3 | $69 |
| Johnson & Johnson | 2 | $54 |
| Boston Scientific | 1 | $35 |
| Merck | 2 | $34 |
| Lilly USA, LLC | 1 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| AbbVie | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
How this compares
$805 in reported general payments places this provider in the 55th percentile of 68 gastroenterology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 12 | $3,686 |
| Ursodiol | 15 | $2,598 |
| Colestipol Hcl | 11 | $1,265 |
| Omeprazole | 61 | $787 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 39 | $494 |
| Carvedilol | 24 | $128 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Portland
- Douglas HowellPortland$1.2M
- Martin MoehlenPortland$340K
- Fernando CalmetPortland$51K
- Marina KimPortland$33K
- Andrew HsuPortland$4K
- Eric VecchioPortland$3K
- Andreas StefanPortland$2K
- Noemi BaffyPortland$1K
- Daniil RolshudPortland$1K
- Cristina RutherfordPortland$670
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.